Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.
Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.
Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.
In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.
Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.
Asensus Surgical (NYSE American: ASXC) announced a leasing agreement with Saiseikai Shiga Hospital in Japan for the Senhance® Surgical System. This partnership marks a significant step in expanding the hospital's robotic surgery capabilities. The Senhance system is known for its advanced features, including haptic feedback and 3D visualization, enhancing surgical precision and patient outcomes. The collaboration aims to integrate these technologies into various surgical specialties, promoting the benefits of Performance-Guided Surgery.
Asensus Surgical, Inc. (NYSE American: ASXC) has announced that the Evangelical Hospital Goettingen-Weende in Germany will become its 7th Senhance Hospital. The hospital will lease a Senhance® Surgical System to enhance their laparoscopic program. This system incorporates advanced features like augmented intelligence and 3D visualization, aiming to improve patient outcomes. Asensus is focusing on Performance-Guided Surgery, providing surgeons with tools to optimize surgical procedures.
Asensus Surgical, Inc. (NYSE American: ASXC) will participate in the H. C. Wainwright 24th Annual Global Investment Conference in New York City on September 12, 2022, at 9:30 AM ET. CEO Anthony Fernando and CFO Shameze Rampertab will host a fireside chat, accessible via a live webcast on the company's investor relations page. The conference aims to enhance investor engagement and share insights about Asensus's innovative Performance-Guided Surgery™ and Digital Laparoscopy technologies. A replay of the session will be available for 90 days on their website.
Asensus Surgical, Inc. (ASXC) reported its Q2 2022 results with a revenue of $1.0 million, a slight decrease from $1.1 million in Q2 2021. Operating expenses increased to $18.2 million, leading to a net loss of $19.6 million or $0.08 per share. The company noted a 34% growth in procedures utilizing the Senhance System, totaling over 670 operations, with a 77% increase in the EMEA region. As of June 30, 2022, cash and investments stood at approximately $103.8 million. Asensus aims to enhance its Performance-Guided Surgery capabilities and expand its digital surgery platform.
Asensus Surgical announced the sale of a Senhance Surgical System to their distribution partner for placement in a hospital located in the Commonwealth of Independent States (CIS). This innovative system revolutionizes laparoscopic procedures through its advanced features, including 3mm instruments, haptic feedback, and an AI-powered platform. The company emphasizes that this partnership aims to enhance patient outcomes and surgical capabilities.
Asensus remains committed to transforming surgical practices with state-of-the-art technology and continuous innovation in performance-guided surgery.
Asensus Surgical, Inc. (NYSE American: ASXC) will announce its 2022 second quarter financial and operational results on August 8, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. This medical device company is focused on digitizing surgical interfaces to enhance surgical outcomes through its Performance-Guided Surgery™ platform. The Senhance Surgical System, powered by the Intelligent Surgical Unit, combines digital laparoscopy with augmented intelligence to improve surgeon control and reduce variability.
Asensus Surgical announced the installation of a Senhance Surgical System at the University Hospital Tübingen, marking its sixth facility in Germany. The system will enhance gynecological procedures and is part of a research collaboration aimed at collecting data on surgical outcomes. The Senhance platform incorporates advanced features like augmented intelligence, haptic feedback, and the ability to utilize the smallest surgical instruments in robotic surgery. Asensus aims to improve surgical precision and patient outcomes through its Intelligent Surgical Unit technology.
Asensus Surgical, Inc. (NYSE American: ASXC) announced participation in the Society of Robotic and Digital Surgery Conference from June 30 to July 3, 2022, in Florida. The event aims to engage surgeons and hospital administrators to explore innovative technologies for improved surgical outcomes. The Senhance Surgical System, leveraging augmented intelligence and machine learning, continues to see global usage growth. Dr. Amit Trivedi will present on Performance-Guided Surgery using Senhance, emphasizing its impact on bariatrics.
Asensus Surgical, Inc. (NYSE American: ASXC) will participate in the H. C. Wainwright Global Investment Conference in Miami, Florida. The fireside chat will occur on Tuesday, May 24, 2022, at 12:00 pm Eastern Time. Interested parties can access the webcast on the company's investor relations page, with a replay available for 90 days. Asensus Surgical focuses on digitizing the surgical experience with its Senhance® Surgical System and Intelligent Surgical Unit™ (ISU™), aiming to improve surgical outcomes through machine vision and augmented intelligence.
Asensus Surgical, Inc. (ASXC) reported its Q1 2022 results, highlighting a 31% increase in global procedures to over 650. Revenue stood at $1.1 million, down from $2.1 million in Q1 2021. Operating expenses rose to $18.2 million from $14.4 million year-over-year. The company incurred a net loss of $19.1 million or $0.08 per share, compared to $17.3 million or $0.08 per share in the prior year. As of March 31, 2022, cash and investments totaled approximately $118.5 million. The company expects significant advancements in its technology and market presence throughout 2022.
FAQ
What is the current stock price of Asensus Surgical (ASXC)?
What is the market cap of Asensus Surgical (ASXC)?
What does Asensus Surgical, Inc. do?
Where is Asensus Surgical headquartered?
What is the Senhance® Surgical System?
What is the latest innovation from Asensus Surgical?
In which regions is the Senhance® Surgical System available?
Has Asensus Surgical recently partnered with any hospitals?
What is the merger agreement with KARL STORZ about?
When is the merger with KARL STORZ expected to close?
Will Asensus Surgical continue to be publicly traded after the merger?
How can I learn more about Asensus Surgical's products?
